<DOC>
	<DOCNO>NCT02461329</DOCNO>
	<brief_summary>The purpose study determine whether volume therapy solution gelatine negative impact coagulation , platelet function , renal function comparison crystaloid solution ( Ringerfundin ) .</brief_summary>
	<brief_title>Comparison Effects Gelatine Versus Balanced Crystalloid Solution Volume Therapy</brief_title>
	<detailed_description>After obtain research ethic committee approval , 50 patient , undergo elective surgery hip replacement include . The informed consent must sign prior randomization . After arrive operation theatre , patient inform consent inclusion exclusion criterion review . Afterwards , patient randomize one two group . Prior anaesthesia induction , blood thrombocyte function test , coagulation test thrombelastometry wil drawn via metal cannula . A large bore peripheral venous cannula ( G18 ) introduce . In case ASA status III high base cardiovascular morbidity arterial catheter via radial artery invasive blood pressure monitoring introduce . Urinary catheter introduce monitor intraoperative diuresis . A continuous crystalloid infusion n dose 5 ml/kg/hour administer basal fluid substitution . The volume replacement use blind gelatine/crystalloid solution perform via fluid challenge ( repeat 250 ml fluid bolus 5 minute interval ) hemodynamic target ( increase blood pressure , decrease heart rate ) , case decrease MAP 65 mm Hg ( 16 ) 70 mmHg preexist hypertension . The hemodynamic variable fluid challenge exactly record . In case patient hemodynamics dot respond fluid challenge , case drop blood pressure le 55 mmHg , bolus 5-10 mg ephedrine ( repeatedly ) administer . Further recorded variable : blood loss ( suction , sponge ) , diuresis , number transfusion administer . Repetitive hemoglobin concentration test use HemoCue 201+ device perform intraoperative blood transfusion trigger 90 g/l hemoglobin concentration use , 100 g/l case patient chronic cardiovascular respiratory disease ( 5 ) . After reach blood loss 1000 ml , blood sample draw laboratory hemoglobin concentration coagulation test . The trigger platelet transfusion thrombocyte count le 50000 x 109 , sings platelet dysfunction thrombelastometry . Tranexamic acid administer case sign fibrinolysis thrombelastometry case life threaten bleeding . At end surgery , second blood sample platelet function test , thrombelastometry , full blood count standard coagulation test draw . The amount blind study infusion , continuous crystalloid solution , transfusion ephedrine administer , diuresis blood loss record . Blood urea creatinine , diuresis , coagulation full blood count record postoperatively . Hospital ICU length stay , hospital 90-day mortality follow .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Blood Platelet Disorders</mesh_term>
	<mesh_term>Blood Loss , Surgical</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Polygeline</mesh_term>
	<criteria>patient schedule elective hip replacement surgery age 1985 year sign informed consent inform consent sign traumatic hip fracture anemia ( hemoglobin level &lt; 100 g/l ) allergy study drug and/or multiple allergy chronic heart failure LVEF &lt; 30 % shock state coagulopathy thrombocytopenia thrombocytopathy chronic kidney disease oliguria chronic antiplatelet drug medication</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Hip Replacement , Total</keyword>
	<keyword>Gelatine solution</keyword>
	<keyword>Balanced Crystaloid Solution</keyword>
	<keyword>Volume therapy</keyword>
	<keyword>Platelet aggregation</keyword>
</DOC>